{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011024","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.198189+00:00","generated_at":"2026-06-04T09:07:08.507104+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AgeX Therapeutics reports FY2023 net loss $14.8M; cash only $0.3M; going concern doubt","bullets":["Net loss $14.8M in FY2023 vs $10.5M in FY2022; EPS ($13.73) vs ($9.70) (basic/diluted).","Cash and equivalents $0.3M at Dec 31, 2023; $4.5M owed to Juvenescence under line of credit.","Operating expenses rose to $10.1M from $7.0M, mainly due to merger due diligence and legal fees.","AgeX expresses substantial doubt about going concern; cash insufficient for next 12 months.","Stockholders approved merger with Serina Therapeutics; line of credit increased $4.4M, repayment extended to May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011024","json":"https://secwatch.observer/filing/0001493152-24-011024.json","markdown":"https://secwatch.observer/filing/0001493152-24-011024.md","text":"https://secwatch.observer/filing/0001493152-24-011024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/0001493152-24-011024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:07:08.507104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8d1913f78e0bf488cfb945ac978bb8cb862af0c","claim":"Serina Therapeutics, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On March 22, 2024, AgeX issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/0001493152-24-011024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}